Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

SMG

Scotts Miracle-Gro Q2 Sales Decline 7%

The Scotts Miracle-Gro Company has reported its second-quarter results, showing a 7% decline in total company sales to $1.42 billion from $1.53 billion in the prior year. U.S. consumer sales decreased by 5% to $1.31 billion from $1.38 billion in the same period last year. However, the company's gross margin rates showed significant improvement, with GAAP gross margin rate of 38.6% and non-GAAP adjusted gross margin rate of 39.1%, reflecting 820 and 380 basis point improvements over the prior year, respectively.

The company's non-GAAP adjusted EBITDA for the quarter was $402.8 million, marking an improvement of $6.5 million over the previous year. The net leverage also decreased to 4.41x from the prior year's 6.95x.

The company's GAAP EPS for the quarter was $3.72, while non-GAAP adjusted EPS stood at $3.98. This represents an improvement in both metrics compared to the same quarter a year ago.

The press release also highlights the company's affirmation of its full-year U.S. consumer segment net sales, consolidated adjusted gross margin, adjusted EBITDA, and free cash flow guidance. The company mentioned that consumer purchases, measured through point-of-sale (POS) data from its largest retailers, saw double-digit increases in consumer takeaway for the second consecutive quarter.

Despite the decline in sales, the company has made substantial progress in key financial metrics, supporting its full-year guidance. The improvements in gross margin rates and non-GAAP adjusted EBITDA, along with the decrease in net leverage, indicate a positive financial trajectory for The Scotts Miracle-Gro Company. As a result of these announcements, the company's shares have moved -11.2% on the market, and are now trading at a price of $47.54. For the full picture, make sure to review Scotts Miracle-Gro's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS